Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ixekizumab in the Treatment of Bullous Pemphigoid

Trial Profile

Ixekizumab in the Treatment of Bullous Pemphigoid

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Bullous pemphigoid
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Dec 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 11 Dec 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Jul 2019.
    • 03 Oct 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top